Novo Nordisk is expanding development of amycretin, an amylin–GLP-1 combination, after Phase II data showed substantial reductions in body weight and blood glucose in patients with diabetes. The company announced it will move amycretin into pivotal diabetes trials and broaden its clinical program beyond obesity-focused development. Phase II results reported up to ~14.5% weight loss over eight months for the injectable amylin–GLP-1 combination and promising glycemic control compared with comparator arms. Novo said it will use the Phase II dataset to design registrational studies and is adding populations and endpoints to support broader regulatory filings. The shift underscores Big Pharma’s strategy to diversify incretin-era portfolios after mixed signals in neurodegeneration, and signals intensified competition across next-generation metabolic therapies.